Mercury Laboratories Ltd
NSE: BSE: 538964
₹780
(1.04%)
Thu, 12 Mar 2026, 09:46 pm
Market Cap926.4M
PE Ratio19.84
Dividend0.45
Health Technology
Pharmaceuticals: Major
24.5KMercury Laboratories Analysis
dividend
- Dividends paid are thoroughly covered by earnings (13.5x coverage).
- Dividend payments have increased, but Mercury Laboratories only paid a dividend in the past 5 years.
- Whilst dividend payments have been stable, Mercury Laboratories has been paying a dividend for less than 10 years.
- Mercury Laboratories's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Mercury Laboratories's dividend is below the markets top 25% of dividend payers in India (3.08%).
health
- Mercury Laboratories is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Mercury Laboratories is profitable, therefore cash runway is not a concern.
- Mercury Laboratories is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (86.8%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 5x debt.
- Mercury Laboratories's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (48.8% vs 19.8% today).
- Interest payments on debt are well covered by earnings (EBIT is 5.3x coverage).
- Mercury Laboratories's level of debt (19.8%) compared to net worth is satisfactory (less than 40%).
- High level of physical assets or inventory.
management
- The tenure for the Mercury Laboratories board of directors is about average.
- Rajendra's remuneration is lower than average for companies of similar size in India.
- Rajendra's compensation has been consistent with company performance over the past year, both up more than 20%.
misc
- Mercury Laboratories is not covered by any analysts.
- Mercury Laboratories has significant price volatility in the past 3 months.
past
- Mercury Laboratories's 1-year earnings growth exceeds its 5-year average (13.7% vs -2.4%)
- Mercury Laboratories's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.
- Mercury Laboratories used its assets less efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Mercury Laboratories's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- Mercury Laboratories has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- Mercury Laboratories's earnings growth has not exceeded the IN Pharmaceuticals industry average in the past year (13.7% vs 22.7%).
value
- Mercury Laboratories is good value based on assets compared to the IN Pharmaceuticals industry average.
- Mercury Laboratories is good value based on earnings compared to the IN Pharmaceuticals industry average.
- 538964 outperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 538964 outperformed the Market in India which returned -14.5% over the past year.
- BSE:538964 is up 7.7% along with the Pharmaceuticals industry (6.8%) over the past month.
- BSE:538964 is up 7.7% along with the India market (8%) over the past month.
- Mercury Laboratories's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Mercury Laboratories's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- Mercury Laboratories is overvalued based on earnings compared to the India market.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800